2017 Volume 8 Issue 1 Pages 43-47
【Aim】This study examined the IL-6 adsorption performance of sepXiris100® over time when used in clinical practice from July, 2014. sepXiris100® is a continuous renal replacement therapy (CRRT) membrane produced by the Baxter Corp. 【Methods】Eight participants took part in the study. CRRT therapy data were recorded if IL-6 clearance was more than 1,000pg/mL after the first 15min of therapy. IL-6 clearance was measured at 15min, 1h, 24h and 48h after the start of therapy. 【Results】Mean IL-6 clearance （mL/min） was 17.3±5.1 at 15min, 7.2±7.1 at 1h, 6.5±5.6 at 24h and 10.2±11.8 at 48h. 【Conclusion】At 1h after therapy started, there was a marked decrease in IL-6 clearance compared with the first 15min of therapy. This sharp decrease did not continue and adsorption seemed to level out within 24h and increased slightly at 48h.
